Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if DYN is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
50 top institutions tracked
Last 13F trend: distributing (light)
Unlock crowding heatmapUnlock filer discoverySentiment: bearish
Last trade: buy 8 days ago
Red flags: 1
245 filers reported a long position in DYN for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | $686.6M | 30.9M | +0.4% |
| BlackRock, Inc. | $275.5M | 12.4M | +6% |
| Jupiter Topco LLC | $266.6M | 12M | — |
| FMR LLC | $248.9M | 11.2M | +25.8% |
| STATE STREET CORP | $165.6M | 7.5M | +12.1% |
| Orbis Allan Gray Ltd | $155.6M | 7M | +3.6% |
| Atlas Venture Life Science Advisors, LLC | $151M | 6.8M | -25.5% |
| VANGUARD CAPITAL MANAGEMENT LLC | $140.2M | 6.3M | -1.5% |
| TCG Crossover Management, LLC | $102.5M | 4.6M | Unchanged |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $89.9M | 4M | -2.7% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.